XML 28 R16.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Segments of Business and Geographic Areas | 9 Months Ended
--- | ---
Oct. 01, 2017
Segment Reporting [Abstract] |
Segments of Business and Geographic Areas | SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS SALES BY SEGMENT OF BUSINESS
|  | Fiscal Third Quarters Ended
(Dollars in Millions) |  | October 1, 2017 |  | October 2, 2016 |  | Percent Change
Consumer |  |  |  |  |  |
United States |  | $ | 1,285 |  |  | 1,291 |  |  | (0.5 | )%
International |  | 2,071 |  |  | 1,970 |  |  | 5.1 |
Total |  | 3,356 |  |  | 3,261 |  |  | 2.9 |
Pharmaceutical |  |  |  |  |  |
United States |  | 5,816 |  |  | 5,042 |  |  | 15.4 |
International |  | 3,879 |  |  | 3,358 |  |  | 15.5 |
Total |  | 9,695 |  |  | 8,400 |  |  | 15.4 |
Medical Devices |  |  |  |  |  |
United States |  | 3,189 |  |  | 3,048 |  |  | 4.6 |
International |  | 3,410 |  |  | 3,111 |  |  | 9.6 |
Total |  | 6,599 |  |  | 6,159 |  |  | 7.1 |
Worldwide |  |  |  |  |  |
United States |  | 10,290 |  |  | 9,381 |  |  | 9.7 |
International |  | 9,360 |  |  | 8,439 |  |  | 10.9 |
Total |  | $ | 19,650 |  |  | 17,820 |  |  | 10.3 | %
|  | Fiscal Nine Months Ended
(Dollars in Millions) |  | October 1, 2017 |  | October 2, 2016 |  | Percent Change
Consumer |  |  |  |  |  |
United States |  | $ | 4,186 |  |  | 4,033 |  |  | 3.8 | %
International |  | 5,876 |  |  | 5,842 |  |  | 0.6 |
Total |  | 10,062 |  |  | 9,875 |  |  | 1.9 |
Pharmaceutical |  |  |  |  |  |
United States |  | 15,698 |  |  | 15,123 |  |  | 3.8 |
International |  | 10,877 |  |  | 10,109 |  |  | 7.6 |
Total |  | 26,575 |  |  | 25,232 |  |  | 5.3 |
Medical Devices |  |  |  |  |  |
United States |  | 9,510 |  |  | 9,118 |  |  | 4.3 |
International |  | 10,108 |  |  | 9,559 |  |  | 5.7 |
Total |  | 19,618 |  |  | 18,677 |  |  | 5.0 |
Worldwide |  |  |  |  |  |
United States |  | 29,394 |  |  | 28,274 |  |  | 4.0 |
International |  | 26,861 |  |  | 25,510 |  |  | 5.3 |
Total |  | $ | 56,255 |  |  | 53,784 |  |  | 4.6 | %
INCOME BEFORE TAX BY SEGMENT
|  | Fiscal Third Quarters Ended
(Dollars in Millions) |  | October 1, 2017 |  | October 2, 2016 |  | Percent Change
Consumer(1) |  | $ | 878 |  |  | 679 |  |  | 29.3 | %
Pharmaceutical(2) |  | 2,857 |  |  | 3,309 |  |  | (13.7 | )
Medical Devices(3) |  | 1,383 |  |  | 1,526 |  |  | (9.4 | )
Segments operating profit |  | 5,118 |  |  | 5,514 |  |  | (7.2 | )
Less: Expense not allocated to segments (4) |  | 328 |  |  | 233 |  |  |
Worldwide income before tax |  | $ | 4,790 |  |  | 5,281 |  |  | (9.3 | )%
|  | Fiscal Nine Months Ended
(Dollars in Millions) |  | October 1, 2017 |  | October 2, 2016 |  | Percent Change
Consumer(1) |  | $ | 2,132 |  |  | 1,816 |  |  | 17.4 | %
Pharmaceutical(2) |  | 9,934 |  |  | 10,340 |  |  | (3.9 | )
Medical Devices(3) |  | 3,938 |  |  | 4,041 |  |  | (2.5 | )
Segments operating profit |  | 16,004 |  |  | 16,197 |  |  | (1.2 | )
Less: Expense not allocated to segments (4) |  | 891 |  |  | 718 |  |  |
Worldwide income before taxes |  | $ | 15,113 |  |  | 15,479 |  |  | (2.4 | )%
(1) Includes a gain of $0.4 billion from the divestiture of COMPEED® (2) Includes a positive adjustment of $0.5 billion to previous reserve estimates in the fiscal nine months of 2016. Includes acquisition costs related to the Actelion acquisition of $0.4 billion and $0.6 billion in the fiscal third quarter and fiscal nine months of 2017, respectively. Includes a gain of $0.2 billion related to monetization of future royalty receivables in the fiscal nine months of 2017. Includes a gain of $0.3 billion and $0.2 billion in the fiscal nine months of 2017 and 2016, respectively, related to the sale of certain investments in equity securities held by Johnson & Johnson Innovation - JJDC, Inc. (3) Includes a restructuring related charge of $0.2 billion and $0.1 billion in the fiscal third quarters of 2017 and 2016, respectively. Includes a restructuring related charge of $0.5 billion and $0.4 billion in the fiscal nine months of 2017 and 2016, respectively. Includes litigation expense of $0.1 billion and $0.1 billion in the fiscal third quarter of 2017 and 2016, respectively. Includes litigation expense of $0.5 billion and $0.7 billion in the fiscal nine months of 2017 and 2016, respectively. Includes an asset impairment of $0.2 billion primarily related to the insulin pump business in the fiscal nine months of 2017. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense. SALES BY GEOGRAPHIC AREA
|  | Fiscal Third Quarters Ended
(Dollars in Millions) |  | October 1, 2017 |  | October 2, 2016 |  | Percent Change
United States |  | $ | 10,290 |  |  | 9,381 |  |  | 9.7 | %
Europe |  | 4,308 |  |  | 3,832 |  |  | 12.4 |
Western Hemisphere, excluding U.S. |  | 1,569 |  |  | 1,396 |  |  | 12.4 |
Asia-Pacific, Africa |  | 3,483 |  |  | 3,211 |  |  | 8.5 |
Total |  | $ | 19,650 |  |  | 17,820 |  |  | 10.3 | %
|  | Fiscal Nine Months Ended
(Dollars in Millions) |  | October 1, 2017 |  | October 2, 2016 |  | Percent Change
United States |  | $ | 29,394 |  |  | 28,274 |  |  | 4.0 | %
Europe |  | 12,398 |  |  | 11,769 |  |  | 5.3 |
Western Hemisphere, excluding U.S. |  | 4,522 |  |  | 4,269 |  |  | 5.9 |
Asia-Pacific, Africa |  | 9,941 |  |  | 9,472 |  |  | 5.0 |
Total |  | $ | 56,255 |  |  | 53,784 |  |  | 4.6 | %

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration